Recent Updates
Recently added Catalysts

VK2735

Phase 3

Weight Loss | Small molecule | Metabolic |Viking Therapeutics, Inc.|Last Updated: Apr 7, 2026

Target and mechanism

Molecular targetGLP-1 and GIP receptors
Target classReceptors
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials5
Total Enrollment6,148

FDA Designations

No designations recorded

Clinical trial landscape

VK2735 · 5 trials · 2 indications

Phase 3 2Phase 2 2Phase 1 1
NCT07104383VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)Weight Loss
ACTIVE NOT_RECRUITING1,100 Analytics
NCT07104500VK2735 for Weight Management Phase 3Weight Loss
ACTIVE NOT_RECRUITING4,500 Analytics
PHASE3ACTIVE NOT_RECRUITING
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Weight Loss
NCT071043831,100
Unlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
VK2735 for Weight Management Phase 3
Weight Loss
NCT071045004,500
Unlock trial analytics

Study Endpoints

Primary Endpoints

Percent change in body weight from baseline to Week 78 in body weight
78 Weeks
Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment
78 Weeks
Percent (relative) change from baseline in body weight after 13 weeks of treatment
13 Weeks

To measure the efficacy of oral VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

Percent (relative) change from baseline to Week 13 in body weight
13 weeks

To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)
8 days

To evaluate the safety and tolerability of single doses of subcutaneous injections of VK2735 in healthy participants

Secondary Endpoints

Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment
78 Weeks
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13. Observed and change from baseline in body weight (kg) after 13 weeks of treatment
13 Weeks
Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13
13 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Placebo AssignmentPLACEBO_COMPARATORVK2735 Placebo Comparator Once Weekly
Active Assignment (Dose #1)EXPERIMENTALVK2735 7.5mg Once Weekly
Active Assignment (Dose #2)EXPERIMENTALVK2735 12.5mg Once Weekly
Active Assignment (Dose #3)EXPERIMENTALVK2735 17.5mg Once Weekly
Active Assignment (Dose 1)EXPERIMENTALVK2735 7.5mg Once Weekly
Active Assignment (Dose 2)EXPERIMENTALVK2735 12.5mg Once Weekly
Active Assignment (Dose 3)EXPERIMENTALVK2735 17.5mg Once Weekly
Active Assignment (Dose #4)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #5)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
Active Assignment (Dose #6)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
VK2735 (Placebo)PLACEBO_COMPARATORPlacebo
VK2735 (Dose #1)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #2)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #3)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist
VK2735 (Dose #4)EXPERIMENTALVK2735 is a peptide GLP-1 and GIP dual agonist
Placebo (Part A)PLACEBO_COMPARATORPlacebo administered SC once in healthy participants
VK2735 (Part A)EXPERIMENTALEscalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.
Placebo (Part B)PLACEBO_COMPARATORPlacebo administered SC once weekly for four weeks in healthy participants
VK2735 (Part B)EXPERIMENTALEscalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.
VK2735 (Part C )PLACEBO_COMPARATORPlacebo administered orally daily for 28 days in healthy participants
VK2735 (Part C)EXPERIMENTALEscalating doses of VK2735 administered daily (PO) in healthy participants.

Interventions

NameTypeDescription
VK2735DRUGVK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
PlaceboDRUGMatching Placebo to VK2735
VK2735 PlaceboDRUGAdministered orally
VK2735 DrugDRUGAdministered orally
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites127

Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent 2. Body mass index (BMI) ≥27 kg/m2 3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screenin...

Countries:United StatesPuerto RicoAustralia
Unlock Eligibility Criteria

Frequently asked questions about VK2735

What is VK2735 used for?

VK2735 is an investigational small molecule being developed for weight loss. It is in Phase 3 clinical trials for weight management, including a study specifically in patients with type 2 diabetes. The drug is also being evaluated for NASH in an early-phase trial.

What does VK2735 target?

VK2735 targets the GLP-1 and GIP receptors. By acting on these receptors, the drug is designed to influence metabolic pathways involved in weight regulation. This dual targeting is a key feature of its mechanism of action.

Who makes VK2735?

VK2735 is being developed by Viking Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol VKTX. The company is conducting clinical trials for the drug across multiple phases.

What phase is VK2735 in?

VK2735 is currently in Phase 3 clinical development for weight loss. It has completed Phase 1 and Phase 2 trials. The drug is investigational and not yet approved by regulatory authorities.

What clinical trials is VK2735 in?

VK2735 is in two active Phase 3 trials: NCT07104383 for weight management in type 2 diabetes and NCT07104500 for weight management, with enrollments of 1,100 and 4,500 respectively. Completed trials include NCT05203237 (Phase 1) and NCT06068946 (Phase 2).

Is VK2735 the same as any other drug?

No alternative names for VK2735 have been reported. The drug is identified solely by its code name VK2735 in clinical trial registries and company communications.